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 Introduction 
 Hormone-refractory prostate cancer (PCa) represents 
the end stage of a progressive and fatal disease for which 
only palliative treatment options exist. Numerous con-
cepts have been proposed to explain the biological pro-
gression of hormone-sensitive PCa to hormone-resis-
tant PCa including stromal-epithelial interactions  [1, 2] , 
changes in androgen receptors  [3] , cell cycle machinery 
impairment  [4] , and abnormal signaling pathways  [1, 5–
8] . Currently, serotonin is considered to be of importance 
in the progression of PCa towards the hormone-refrac-
tory state  [1, 9, 10] . The basis for this hypothesis is the 
reported expression of 5-HT receptors in LNCaP and 
PC3 cell lines  [5, 6] . Serotonin-mediated mitogenic activ-
ity in vitro  [11] and in vivo  [12] as well as effects of 5-HT 
agonists/antagonists have been reported  [5, 6, 13, 14] .
5-HT was thus described as a potent mitogen in vitro act-
ing in the   M concentration range and stimulating pro-
liferation of PCa cell lines  [11] . The serotonin receptor 
subtypes 5HTR1a, -1b, -2b and -4 were recently identified 
and characterized in PCa cell lines  [5, 6] . These studies, 
involving the administration of 5-HT agonists/antago-
nists in vitro reported that stimulation at low concentra-
tions (nM to   M ) leads to increased proliferative activity, 
while inhibition leads to decreased proliferation in a con-
centration-dependent manner  [5, 6, 13] . For such experi-
ments, hormone-dependent (LNCaP), hormone-inde-
pendent (PC3, DU145) and androgen-responding (22RV1) 
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 Abstract 
 Objectives: To investigate the effects of serotonin and mela-
tonin (MLT) on the regulation of malignant growth and the 
activity of serotonin receptors (5HTR1a/-1b) in prostate can-
cer (PCa) cell lines.  Materials and Methods: In four PCa cell 
lines (LNCaP, 22RV1, PC3, DU145) and two reference cell lines 
5HTR1a and -1b, relative mRNA expression levels were as-
sessed. Different serotonin and MLT receptor agonists and 
antagonists were used in stimulation and inhibition experi-
ments.  Results: mRNA expression of 5HTR1b was higher 
than that of 5HTR1a in all PCa cell lines. Serotonin showed a 
significant growth stimulatory effect in all PCa lines. The 
5HTR1a and -1b agonists/antagonists did not significantly af-
fect viability. MLT inhibited viability only in PC3 cells. Simi-
larly, the 5HTR1a antagonist induced apoptotic changes in 
PC3 cells only at 10 –4  M , while the 5HTR1b antagonist in-
duced necrosis at 10 –4  M in all cell lines. Cell cycle alterations 
were seen in PC3 and DU145 cells under the influence of the 
5HTR1a antagonist.  Conclusions: Serotonin receptor antag-
onists and agonists as well as MLT influence viability and 
apoptosis of PCa cell lines at supraphysiologic concentra-
tions. In contrast to other reports, our results do not support 
a regulatory role of serotonin or MLT receptor activation or 
inhibition in PCa growth. 
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human PCa cell lines are used as convenient in vitro 
models  [15, 16] .
 The pineal hormone melatonin (MLT) may also be in-
volved in the molecular interactions in different malig-
nancies including PCa  [2, 17–23] . Studies in LNCaP cell 
lines in vivo have shown an inhibition of tumor growth 
by MLT at nM concentrations with decreased expression 
of cell cycle markers  [20] . It was concluded that the anti-
proliferative effects of MLT in LNCaP line were partly 
mediated by MT 1 receptors and influenced the cell cycle 
with the possible induction of apoptotic changes  [20] . 
The data obtained from other studies  [19] on androgen-
deprived LNCaP lines also showed a direct antiprolifera-
tive effect of MLT by impairment of the cell cycle (G 0 /G 1 
arrest)  [21] . Results obtained from studies on MLT activ-
ity in DU145 cell lines have shown cell cycle arrest in the 
G 0 /G 1 phase due to direct stimulation of nuclear MT re-
ceptors  [23] . Membrane-associated receptors are suggest-
ed to be different sites of action of MLT in PC3 cell lines 
 [22] .
 The aims of our work were to investigate the expres-
sion of two serotonin receptors (5HTR1a and 5HTR1b) 
and the effects of serotonin, several serotonin agonists 
and antagonists and MLT in the regulation of malignant 
growth in several PCa cell lines (LNCaP, PC3, DU145, 
22RV1).
 Materials and Methods 
 Cell Culture and Reagents 
 The human PCa cell lines LNCaP (hormone-dependent),
22RV1 (hormone-responding), PC3 and DU145 (hormone-inde-
pendent) were used for in vitro experiments (ATCC). As refer-
ence, human fibroblasts and BPH-1 cell line were used in experi-
ments (DSMZ). The cell lines were cultivated in RPMI 1640 me-
dium supplemented with 10% FBS and 1% MEM (Invitrogen, 
Karlsruhe, Germany) without antibiotics in 75-cm 2 flasks (Grei-
ner, Frickenhausen, Germany). Cellular growth density was eval-
uated as low (LD;  ! 50% visual density) and high (HD; 50–75% 
visual density). Cell counting was performed after trypsinization 
by Cell Coulter Z 2 Particle Count & Size Analyzer (Beckman-
Coulter, Krefeld, Germany).
 Reagents used were: 5-HT, MLT (highly purified  1 99.5%), 
( 8 )-8-OH-DPAT (selective high-affinity 5-HT1a receptor ago-
nist), CGS-12066A maleate salt (5-HT1b receptor agonist), NAN-
190 hydrobromide (5-HT1a receptor antagonist), and methiothe-
pin mesylate salt (5-HT1b receptor antagonist). All these reagents 
were obtained from Sigma-Aldrich, Germany.
 RNA Isolation, cDNA Synthesis, Quantitative PCR 
 Total cellular RNA was isolated using Invisorb  Spin Cell 
RNA Mini Kit (Invitek GmbH, Berlin, Germany). The concentra-
tion of extracted RNA was measured by UV/Vis spectrometry on 
an Ultrospec 3000 (Amersham Biosciences, Little Chalfont, UK). 
cDNA synthesis was performed using SuperScript TM RNAse H 
reverse transcriptase (Invitrogen, Karlsruhe, Germany). The 
mRNA expression levels of the serotonin receptors 5HTR1a/-1b 
were measured by pre-made quantitative PCR assays (primers: 
Hs00265286_s1, Hs00265014_s1) and referred to housekeeping 
genes (HPRT – hypoxantine phosphoribosyltransferase) as inter-
nal control (Applied Biosystems, Foster City, Calif., USA) using a 
Light Cycler instrument (Roche, Mannheim, Germany). The RT-
PCR two-step program used 45 cycles of initial denaturation at 
95 ° C for 600 s; amplification 1 at 95 ° C for 15 s; amplification 2 at 
60 ° C for 15 s; cooling at 40 ° C for 60 s. RT-PCR products were 
analyzed by 2% agarose gel electrophoresis and visualized under 
UV after staining with ethidium bromide.
 Cellular Viability Test in vitro 
 Cells were seeded in 96-well plates with 3,000 cells/well in
100   l RPMI 1640 with 10% FCS for 1 day in order to obtain op-
timal growth and density of no more than 75%. Then, the me-
dium was changed to 100   l RPMI 1640 with 10% charcoal-
stripped, hormone-free FCS (Biochrom AG, Berlin, Germany). 
After 24 h of medium adaptation, the 5HTR1a- or -1b-specific 
agonists at concentrations from 10 –10 to 10 –6  M and antagonists 
(10 –8 to 10 –4  M ) were added to the medium and incubated for 3 
days. 5-HT was freshly prepared and stored in DMSO stock solu-
tions (10 –1  M ) and diluted in medium to concentrations of 10 –8 to 
10 –4  M . MLT was also freshly prepared and diluted in DMSO to 
1.0  M stock solution, then in medium in concentration ranges of 
10 –11 to 10 –3  M and was administered daily during 4 days of in-
cubation. Cellular viability was studied from 24 to 72 h after in-
cubation with agonists/antagonists by cell proliferation reagent 
WST-1 (Roche, Penzberg, Germany) comparing control cell lines 
incubated with DMSO. For this, 10   l/well WST-1 was added, 
followed by 1–1.5 h of incubation (37 ° C, 5% CO 2 ). Cell viability 
was determined by absorbance measurement at 450 nm (refer-
ence wavelength 620 nm) using a microplate reader (Anthos 
Labtec, Krefeld, Germany). Viability after incubation with ago-
nists/antagonists was expressed relative to control (incubated 
with DMSO).
 Cell Cycle, Apoptosis Analysis by Flow Cytometry 
 Changes in cell cycle of 2  ! 10 4 nuclei were analyzed using 
Cycle Test TM Plus DNA Reagent Kit (Becton Dickinson, Heidel-
berg, Germany) and FACScan (Becton, Dickinson). The early 
 (annexin+/propidium iodide–) and late (annexin+/ propidium io-
dide+) apoptosis was studied by Annexin V-FITC Apoptosis De-
tection Kit I (BD Biosciences, Heidelberg, Germany) according to 
the manufacturer’s instructions.
 Results 
 Basal mRNA Expression Levels of 5HTR1a and 
5HTR1b in PCa Cell Lines 
 The results of the quantification of the relative mRNA 
expression levels of the 5HTR receptor subtypes HTR1a 
and HTR1b corresponding to the growth density are 
shown in  figure 1 . Transcripts were detectable in all cell 
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 Fig. 1. Relative mRNA expression of 
5HTR1a ( a ) and 5HTR1b ( b ) normalized 
to the reference gene HPRT in PCa cell 
lines corresponding to the growth density 
of the cells. 
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 Fig. 2. Relative viability of 22RV1, PC3
and DU145 cell lines (normalized to con-
trol incubated with DMSO) 24 h after in-
cubation with 5-HT. 
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lines (data not shown). The comparison with growth den-
sity showed a higher expression of both 5HTR receptor 
subtypes in HD (50–75%) compared to LD ( ! 50%) in all 
cell lines ( fig. 1 ), with the exception of 5HTR1a expres-
sion in 22RV1 and human fibroblasts.
 Effects of 5-HT and 5HTR1a/-1b Agonists and 
Antagonists on Cellular Viability 
 The cellular viability of 22RV1, PC3 and DU145 cells 
after 24 h of incubation with 5-HT (10 –8 to 10 –4  M ) is 
shown in  figure 2 . The pronounced stimulatory effect 
c
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
10–8 10–7 10–6 10–5 10–4
Concentration (M)
Re
la
tiv
e 
vi
ab
ili
ty
b
0
0.2
0.4
0.6
0.8
1.0
1.2
10–8 10–7 10–6 10–5 10–4
Concentration (M)
Re
la
tiv
e 
vi
ab
ili
ty
0
0.2
0.4
0.6
0.8
1.0
1.2
10–8
a
10–7 10–6 10–5 10–4
Concentration (M)
Re
la
tiv
e 
vi
ab
ili
ty
Antagonist 5HTR1b (methiothepin)
Antagonist 5HTR1a (NAN-190)
 Fig. 3. Cellular viability in LNCaP ( a ), PC3 
( b ) and DU145 ( c )  after 48-hour incuba-
tion with NAN-190 hydrobromide and 
 methiothepin mesylate salt in a concentra-
tion range of 10 –8 to 10 –4  M . 
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with increased cellular growth was observed in PC3 cells 
(+21.2, +31.8 and +59.5% at 10 –8 , 10 –6 and 10 –4  M , respec-
tively). In DU145 cells, a slight stimulatory effect was ob-
served only at 10 –4  M (+28.2%). LNCaP and 22RV1 cells 
did not respond at all to 5-HT stimulation (data not 
shown).  Figure 3 gives the results of cell viability assess-
ment without 5-HT stimulation in the presence of the 5-
HT1a antagonist NAN-190 hydrobromide or the 5-HT1b 
antagonist methiothepin mesylate. After 48 h of incuba-
tion, cellular viability was not affected by the antagonist 
in the concentration range of 10 –8 to 10 –5  M . At a concen-
tration of 10 –4  M , no changes were observed after 5HTR1a 
inhibition. A concentration of 10 –4  M of methiothepin me-
sylate was cytotoxic and caused total necrosis after 12 h of 
incubation. A 24-hour incubation of the cell lines PC3 and 
DU145 after 24 h with NAN-190 and methiothepine me-
sylate in a constricted concentration range between 10–5 
and 10–4 M confirmed these results (fig. 4). Methiothepine 
mesylate at a concentration of >10–5 M induced dramatic 
cell death. In the same experiments using the 5HTR1a and 
-1b agonists ( 8 )-8-OH-DPAT and CGS-12066A, maleate 
salt did not affect cellular viability (data not shown).
 Effects of 5HTR1a/-1b Antagonists on Apoptosis 
 In DU145 cells, significant apoptotic changes were ob-
served after 24-hour incubation with NAN-190 at a con-
centration of 10 –4  M . The changes were significant for 
early and late apoptosis. Incubation with NAN-190 did 
not induce apoptosis, but necrosis in PC3 cell culture was 
seen at a concentration of 10 –4  M ( fig. 5 ).
 Changes in Cell Cycle Phases after Incubation with 
5HTR1a/-1b Antagonists 
 Figure 6 summarizes the effects seen on cell cycle. In 
PC3 and DU145 cell lines, the highest proportion of cells 
which underwent G 0 –G 1 phase arrest were detected after 
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 Fig. 4. Cellular viability test (WST-1) in 
PC3 ( a ) and DU145 ( b ) after 24-hour incu-
bation with NAN-190 hydrobromide and 
methiothepin mesylate. 
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24 h of incubation with the 5HTR1a antagonist (NAN-
190) at a concentration of 10 –4  M ( fig. 6 ). Methiothepin 
caused no significant changes in cell cycle phases (data 
not shown).
 Effects of MLT on Cellular Viability 
 Treatment of PC3, DU145 and 22RV1 cells with MLT 
showed time- and dose-dependent effects on cellular vi-
ability in supraphysiologic concentrations only ( fig. 7 ). 
After 72 h of incubation with MLT in the concentration 
range 10 –8 to 10 –3  M , no inhibitory effects were observed 
(data not shown), while at supraphysiologic concentra-
tions of MLT (10 –3 to 10 –2  M ) a marked concentration-de-
pendent decrease in cellular viability was seen ( fig. 7 ).
 Discussion 
 PCa progression remains a complex process which still 
evades complete understanding. Many biologic factors ca-
pable of influencing or regulating cell growth have been 
implicated and probably are involved  [24, 25] . MLT has 
been shown to have an influence on cancer cell growth in 
several cancer entities including PCa cells growing in vitro 
 [26, 27] . There may even been potential therapeutic impli-
cations for MLT  [28] . All these reasons make MLT a sub-
stance of interest in PCa research, and we therefore under-
took these experiments on MLT receptors in PCa cell lines. 
We found an expression of both 5HTR subtypes 5HTR1a 
and 5HTR1b in the four PCa cell lines used (PC3, DU145, 
 Fig. 5. Effects of NAN-190 on apoptosis af-
ter 24-hour incubation in DU145 ( a ) and 
PC3 ( b ). 
Early apoptosis annexin+/PI–
Late apoptosis annexin–/PI+
0
2
4
6
8
10
12
14
16
5.3
1.3
Control 24 h
a
b
5.1
1.9
10–8
6.7
2.5
10–6
10.1
5.1
10–4
NAN-190 concentration (M)
Pe
rc
en
t c
el
ls
 
0
5
10
15
20
25
30
35
5.3
1.3
Control 24 h
4.3
10.1
10–8
3.2
10.6
10–6
17.1
12.6
10–4
NAN-190 concentration (M)
Pe
rc
en
t c
el
ls
 
 Pirozhok/Meye/Hakenberg/Fuessel/
Wirth 
Urol Int 2010;84:452–460458
 Fig. 7. Cellular viability test in PC3, DU145 
and 22RV1 after 72-hour incubation with 
MLT in a concentration range of 10 –3 to 
10 –2  M . 
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 Fig. 6. Cell cycle arrest in G 0 /G 1 in DU145 
( a ) and PC3 ( b ) cells after 24-hour incuba-
tion with NAN-190. Percentages of cells in 
different phases of the cell cycle (G 0 /G 1 , S, 
G 2 /M) are shown. Control refers to incu-
bation with DMSO. 
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LNCaP and 22RV1) as well as in the BPH-1 line and hu-
man fibroblasts. The relatively low expression of 5HTR1a 
and 5HTR1b receptors observed, however, may signify 
that in nonstimulated PCa cells the 5HTR1a/-1b expres-
sion at mRNA level does not play a significant role in reg-
ulation of growth. Reports in the literature  [5] described 
the qualitative (detected by PCR) and immunohistochem-
ical features of 5HTR1a/-1b, but their functional activity 
may well depend on the quantitative properties.
 In experiments with 5-HT stimulation, we found that 
the stimulatory effect was dose-dependent at 10 –8 to
10 –4  M during the first 24 h and highest at 10 –4  M . The data 
from the Malmö group described a stimulatory effect of 
5-HT on proliferation in DU145 and PC3 cells at 10 –8  M 
with no significant effect on LNCaP cells  [5] . These and 
other authors describe 5-HT as a mitogen in vitro  [5, 11, 
12] . It is possible that with low 5HTR1a/-1b expression and 
high concentrations of 5-HT, the viability and prolifera-
tion effects may be mediated by other types of serotonin 
receptors as other types of serotonin receptors in PCa cell 
lines have been identified (5HTR2b, 5HTR4) with a puta-
tive role in proliferation and differentiation  [6] .
 Our results with 5HTR1a/-1b agonists did not show 
any effect of selective 5HTR1a/-1b stimulation on physi-
ological concentrations. This fact may also support the 
low functional activity of 5HTR1a/-1b receptor subtypes. 
The inhibition experiments showed physiological effects 
on cellular viability in the concentration range 10 –8 to
10 –4  M , and only cytotoxic effects of methiothepin at
10 –4  M . Our data suggest that inhibition of 5HTR1a/-1b 
in physiologic concentrations does not affect cellular vi-
ability. In contrast to our findings, other authors  [5] have 
reported that 5HTR1a inhibition in DU145, PC3 and
LNCaP cells was concentration-dependent and maximal 
at 10 –6  M . However, neither those nor our results support 
a prominent functional role of 5HTR1a/-1b or 5-HT 
stimulation in cell viability in PCa cell lines.
 In agreement with others, we did find a time- and 
dose-dependent effect of MLT on cellular viability in 
PC3, DU145 and 22RV1  [22, 23] . In contrast to a hypoth-
esis reported in the literature, this effect in our observa-
tion did not seem to be related to hormone dependency 
of the cell lines  [19, 20, 26] . Reported maximum MLT 
 inhibitory activity was at high concentrations of 10 –3 to 
10 –2  M after 72 h of continuous incubation  [26] , making 
MLT a potent inhibitor in vitro only in mM concentra-
tions with effects only after prolonged incubation. Our 
data correspond to these reported findings concerning 
concentration range and time effect as well as more ef-
fective inhibition in moderate cellular density (3,000 
cells/well)  [26] . These findings thus somewhat charac-
terize MLT as an antiproliferative agent in PCa cell lines, 
but may cast doubt on the hypothesis that this effect is 
highly specific and of great biological significance in 
PCa.
 Similarly, while a putative role of MLT in apoptosis is 
still controversial, we have observed an apoptotic effect 
of MLT in DU145 and PC3 only at concentrations of
10 –4  M . Since MLT as a pineal hormone exerts its biolog-
ical effect in vivo at n M concentrations  [17, 18] , the ob-
served apoptotic effect in cell culture is highly unlikely to 
be specific.
 Changes in cell cycle due to G 0 /G 1 phase arrest were 
described as one of several possible mechanisms in the 
regulation of proliferation  [4] . We observed a G 0 /G 1 phase 
arrest induced by the 5HTR1a receptor antagonist NAN-
190 after 24 h of incubation at 10 –4  M in PC3 and DU145 
cells. Again, the concentration at which this effect was 
observed does not support a biological significance.
 Conclusions 
 Our results do not support the hypothesis that acti-
vation or inhibition of the serotonin receptor subtypes 
5HTR1a or 5HTR1b plays a prominent role in the control 
of growth and viability of PCa cell lines. Inhibitory ef-
fects of MLT in PCa cell lines in vitro occur at supraphys-
iological concentrations only. Thus, neither MLT nor the 
serotonin receptor subtypes 5HTR1a and 5HTR1b seem 
to have an important role in the in vitro growth regula-
tion of human PCa cell lines.
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